BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33129348)

  • 1. Prognostic value of
    Han S; Choi JY
    Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different
    El-Hennawy G; Moustafa H; Omar W; Elkinaai N; Kamel A; Zaki I; Farid N; El-Kholy E
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of
    Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
    BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive values of interim
    Han S; Kim YI; Woo S; Kim TH; Ryu JS
    Ann Nucl Med; 2021 Apr; 35(4):447-457. PubMed ID: 33471289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The accuracy of
    Tian F; Shen G; Deng Y; Diao W; Jia Z
    Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of SUV
    Diao W; Tian F; Jia Z
    Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-tumor metabolic heterogeneity of gastric cancer on
    Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
    Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity in
    Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.
    Zhu D; Wang L; Zhang H; Chen J; Wang Y; Byanju S; Liao M
    Medicine (Baltimore); 2017 Aug; 96(33):e7813. PubMed ID: 28816978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.
    Chung YS; Kim Y; Kim HS; Lee JY; Kang WJ; Kim S; Kim SW
    J Gynecol Oncol; 2022 May; 33(3):e28. PubMed ID: 35128858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.